BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi T, Asano Y, Akamata K, Aozasa N, Taniguchi T, Noda S, Masui Y, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Modern Rheumatology 2014;23:884-90. [DOI: 10.3109/s10165-012-0755-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. Exp Dermatol 2016;25:287-92. [DOI: 10.1111/exd.12920] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Michalska-Jakubus M, Cutolo M, Smith V, Krasowska D. Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: Integrated effects on microvascular reactivity. Microvasc Res 2019;125:103881. [PMID: 31075243 DOI: 10.1016/j.mvr.2019.103881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Uehara M, Enomoto N, Mikamo M, Oyama Y, Kono M, Fujisawa T, Inui N, Nakamura Y, Suda T. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis. Respir Med 2016;114:18-26. [PMID: 27109807 DOI: 10.1016/j.rmed.2016.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wu Q, Xu WD, Huang AF. Role of angiopoietin-2 in inflammatory autoimmune diseases: A comprehensive review. Int Immunopharmacol 2020;80:106223. [PMID: 31991374 DOI: 10.1016/j.intimp.2020.106223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nakamura K, Asano Y, Taniguchi T, Minatsuki S, Inaba T, Maki H, Hatano M, Yamashita T, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis. J Dermatol 2016;43:912-8. [PMID: 26777734 DOI: 10.1111/1346-8138.13252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bassyouni IH, Sharaf M, Wali IE, Mansour HM. Clinical significance of Angiopoietin-1 in Behcet’s disease patients with vascular involvement. Heart Vessels 2016;31:918-24. [DOI: 10.1007/s00380-015-0686-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Takahashi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Yoshizaki A, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. Br J Dermatol 2016;175:1195-203. [PMID: 27105895 DOI: 10.1111/bjd.14699] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
8 Fukui Y, Miyagawa T, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y. Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis. J Dermatol 2019;46:584-9. [PMID: 31087594 DOI: 10.1111/1346-8138.14914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Taniguchi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sato S. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis. J Rheumatol 2017;44:1198-205. [DOI: 10.3899/jrheum.161092] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
10 Saigusa R, Asano Y, Nakamura K, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Yoshizaki A, Miyazaki M, Tamaki Z, Sato S. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease. Mod Rheumatol 2017;27:618-22. [PMID: 27538472 DOI: 10.1080/14397595.2016.1226472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
11 Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, Takahashi T, Ichimura Y, Noda S, Akamata K, Saigusa R, Miyazaki M, Kuwano Y, Yanaba K, Yoshizaki A, Sato S. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. J Dermatol 2018;45:1425-33. [PMID: 30289572 DOI: 10.1111/1346-8138.14669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Takahashi T, Asano Y, Yamashita T, Nakamura K, Saigusa R, Miura S, Ichimura Y, Toyama T, Hirabayashi M, Taniguchi T, Yoshizaki A, Sato S. A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis. J Eur Acad Dermatol Venereol 2018;32:291-7. [DOI: 10.1111/jdv.14459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]